MXPA05013398A - Solucion estable acuosa de eritropoyetina de origen humano, que no contiene albumina de suero. - Google Patents

Solucion estable acuosa de eritropoyetina de origen humano, que no contiene albumina de suero.

Info

Publication number
MXPA05013398A
MXPA05013398A MXPA05013398A MXPA05013398A MXPA05013398A MX PA05013398 A MXPA05013398 A MX PA05013398A MX PA05013398 A MXPA05013398 A MX PA05013398A MX PA05013398 A MXPA05013398 A MX PA05013398A MX PA05013398 A MXPA05013398 A MX PA05013398A
Authority
MX
Mexico
Prior art keywords
human erythropoietin
serum albumin
stable
aqueous solution
containing serum
Prior art date
Application number
MXPA05013398A
Other languages
English (en)
Inventor
Jin-Seok Oh
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05013398(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of MXPA05013398A publication Critical patent/MXPA05013398A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion provee una formulacion acuosa de eritropoyetina de origen humano que tiene estabilidad durante el almacenamiento por un largo periodo de tiempo sin albumina de suero, en donde la formulacion comprende una cantidad terapeuticamente efectiva de eritropoyetina de origen humano; agente tensioactivo no ionico, alcohol polihidrico aminoacido neutral y alcohol de azucar como los estabilizadores; reactivo isotonico; y reactivo regulador de pH.
MXPA05013398A 2003-06-10 2004-06-07 Solucion estable acuosa de eritropoyetina de origen humano, que no contiene albumina de suero. MXPA05013398A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20030037060 2003-06-10
PCT/KR2004/001358 WO2004108152A1 (en) 2003-06-10 2004-06-07 Stable, aqueous solution of human erythropoietin, not containing serum albumin

Publications (1)

Publication Number Publication Date
MXPA05013398A true MXPA05013398A (es) 2006-03-09

Family

ID=36337525

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013398A MXPA05013398A (es) 2003-06-10 2004-06-07 Solucion estable acuosa de eritropoyetina de origen humano, que no contiene albumina de suero.

Country Status (19)

Country Link
US (1) US8119595B2 (es)
EP (1) EP1641486B1 (es)
JP (1) JP4871720B2 (es)
KR (1) KR100610003B1 (es)
CN (1) CN1802171B (es)
AT (1) ATE553747T1 (es)
AU (1) AU2004244920B2 (es)
BR (1) BRPI0411114B8 (es)
CA (1) CA2528988C (es)
EA (1) EA009676B1 (es)
ES (1) ES2385888T3 (es)
HK (1) HK1093012A1 (es)
MX (1) MXPA05013398A (es)
NO (1) NO20055747L (es)
NZ (1) NZ543859A (es)
PL (1) PL379272A1 (es)
UA (1) UA82241C2 (es)
WO (1) WO2004108152A1 (es)
ZA (1) ZA200509222B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200640492A (en) 2005-02-21 2006-12-01 Lg Life Sciences Ltd Sustained release composition of protein drug
US8546329B2 (en) * 2006-03-22 2013-10-01 Chugai Seiyaku Kabushiki Kaisha Erythropoietin solution preparation
DE102007050165B4 (de) * 2007-10-19 2010-06-17 Stiftung Tierärztliche Hochschule Hannover Stabilisierte Lösung, Verfahren zu deren Herstellung sowie deren Verwendung und Arzneimittel in Form einer stabilisierten Lösung
EP2219602A1 (en) 2007-11-15 2010-08-25 Amgen, Inc Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
WO2010019266A2 (en) * 2008-08-15 2010-02-18 Ironwood Pharmaceuticals, Inc. Stable solid formulation of a gc-c receptor agonist polypeptide suitable for oral administration
MX2012001660A (es) * 2009-08-06 2012-03-26 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para adminstracion oral.
BR112012017982A2 (pt) * 2010-01-19 2016-05-03 Hanmi Science Co Ltd formulações líquidas para conjugado de eritropoietina de longa ação
DK2536742T3 (en) 2010-02-17 2017-09-04 Ironwood Pharmaceuticals Inc TREATMENTS FOR GASTROINTESTINAL DISORDERS
US20140005128A1 (en) 2010-08-11 2014-01-02 Forest Laboratories Holdings Limited Treatments of gastrointestinal disorders
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
WO2013025969A1 (en) 2011-08-17 2013-02-21 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
AU2014243839B2 (en) * 2013-03-13 2019-01-03 Buzzard Pharmaceuticals AB Chimeric cytokine formulations for ocular delivery
EP2832361A1 (en) * 2013-07-29 2015-02-04 Ipsen Pharma S.A.S. Aqueous sustained release compositions of LHRH analogs
DK3287141T3 (da) * 2015-04-21 2021-10-11 Staidson Beijing Biopharmaceuticals Co Ltd Nervevækstfaktorsammensætning og injektionspulver
WO2023098844A1 (zh) * 2021-12-03 2023-06-08 杰科（天津）生物医药有限公司 一种制剂及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
JPS6191131A (ja) 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
DE3729863A1 (de) 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
GB9001987D0 (en) 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
EP1015008B1 (en) * 1997-02-07 2015-08-05 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
AU5649299A (en) * 1998-09-11 2000-04-03 Chugai Seiyaku Kabushiki Kaisha Protein solution preparation and method for stabilizing the same
JP2002541208A (ja) * 1999-04-09 2002-12-03 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド エリトロポイエチンの薬剤組成物
ATE389414T1 (de) * 1999-09-08 2008-04-15 Chugai Pharmaceutical Co Ltd Stabile proteinlösung abgefüllt in einem behältnis aus hydrophobem harz und eine methode zur stabilisierung derselben
AU2001236005A1 (en) * 2000-02-29 2001-09-12 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time
DK1311285T4 (en) 2000-05-15 2017-07-24 Hoffmann La Roche Liquid pharmaceutical composition containing an erythropoietin derivative
SI21258A (sl) * 2002-07-17 2004-02-29 LEK farmacevtska dru�ba d.d. Stabilni farmacevtski pripravek, ki vsebuje eritropoietin in poloksamerni poliol

Also Published As

Publication number Publication date
BRPI0411114B1 (pt) 2020-09-15
ATE553747T1 (de) 2012-05-15
CN1802171A (zh) 2006-07-12
BRPI0411114B8 (pt) 2021-05-25
UA82241C2 (uk) 2008-03-25
CA2528988A1 (en) 2004-12-16
KR20040110994A (ko) 2004-12-31
AU2004244920B2 (en) 2009-07-23
HK1093012A1 (en) 2007-02-23
EP1641486A4 (en) 2008-10-08
EP1641486A1 (en) 2006-04-05
JP2007528842A (ja) 2007-10-18
EP1641486B1 (en) 2012-04-18
CA2528988C (en) 2012-05-01
ES2385888T3 (es) 2012-08-02
JP4871720B2 (ja) 2012-02-08
NZ543859A (en) 2008-01-31
EA009676B1 (ru) 2008-02-28
KR100610003B1 (ko) 2006-08-08
US8119595B2 (en) 2012-02-21
AU2004244920A1 (en) 2004-12-16
EA200501789A1 (ru) 2006-06-30
NO20055747D0 (no) 2005-12-05
ZA200509222B (en) 2006-09-27
US20070293419A1 (en) 2007-12-20
PL379272A1 (pl) 2006-08-21
CN1802171B (zh) 2010-10-13
WO2004108152A1 (en) 2004-12-16
NO20055747L (no) 2006-03-07
BRPI0411114A (pt) 2006-07-18

Similar Documents

Publication Publication Date Title
HK1093012A1 (en) Stable, aqueous solution of human erythropoietin, not containing serum albumin
ATE485835T1 (de) Antikörper enthaltende pharmazeutische lösungen
CO5660273A2 (es) Formulaciones de proteina y anticuerpo de alta concentracion
MY149306A (en) Solid preparation containing an insulin sensitizer
WO2005115406A3 (en) 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
DK1372608T3 (da) Medicinske aerosolformuleringer
GT199900072AA (es) Jarabe antihistaminico estabilizado
WO2006117217A3 (de) Neue verwendung von spiegelmeren
WO2006020935A3 (en) Stabilizing formulations
WO2006003371A3 (en) Herbicidal suspension concentrate formulation
EP1930024A3 (en) G-CSF solution formulations having long-term stability
RS20050662A (en) Liquid formulations of tumor necrosis factor-binding proteins
CA2496540A1 (en) Stable ophthalmic solution comprising latanoprost as active ingredient
WO2003060066A3 (en) Nucleic acid delivery and expression
WO2007035718A3 (en) Crystalline forms of the di-sodium salt of n-(5-chlorosalicyloyl)-8-aminocaprylic acid
WO2002068575A8 (en) Liquid detergent composition exhibiting enhanced α-amylase enzyme stability
EA200400751A1 (ru) Применение дезоксипеганина для лечения клинической депрессии
EP1272655A4 (en) STABILIZATION OF HIGHLY SENSITIVE NUCLEIC ACID COLORS IN AQUEOUS SOLUTION
WO2004075834A3 (en) Stabilized pharmaceutical compositions of safingol and methods of using the same
CA2545880A1 (en) Erythropoietin solution formulation
ATE424399T1 (de) Pharmazeutische zusammensetzungen von risperidon in wässriger lösung
ITUD20040162A1 (it) Procedimento di valutazione dell' instabilita' delle proteine contenute in una bevanda a ph acido
UA90929C2 (ru) Водный гербицидный концентрат суспензии, гербицидное средство и водное гербицидное средство (варианты)
UA40520A (uk) Горілка "відбірна"
BG108668A (en) Use of a copolymer to produce a galenic form containing a peptide or a protein as active agent

Legal Events

Date Code Title Description
FG Grant or registration